ACE2 and COVID-19: Electrolyte imbalances were also one of the most common presentations of COVID-19 and arose as a complication during the course of illness [4,5]. The high prevalence of COVID-19 infection in HT patients could be attributed to the use of angiotensin-converting enzyme (ACE) inhibitors since this COVID-19 virus binds to angiotensin-converting enzyme 2 (ACE2) receptors to enter the target cells [6].